Biocept's Liquid Biopsy Lung Cancer Target Selector Assay to be featured at World Conference on Lung Cancer

Biocept, Inc. BIOC, a molecular diagnostics company commercializing and developing liquid biopsies to improve the detection and treatment of cancer, announces that clinical data from a study conducted with researchers at the University of California, San Diego's Moores Cancer Center indicate that Biocept's lung cancer Target Selector™ assay has high concordance with tumor status in patients with metastatic lung cancer. The clinical data will be presented in a poster presentation at the International Association of Lung Cancer's 16th World Conference on Lung Cancer in Denver on September 8, 2015. "Results of our study indicate that the non-invasive Target Selector™ assay could have a role in managing patients with metastatic lung cancer," said Lyudmila A. Bazhenova, M.D., UC San Diego Moores Cancer Center. "For example, a patient was correctly identified as having an emerging T790M resistance to Tyrosine Kinase Inhibitors (TKI) with the Target Selector™ assay prior to confirmation by tissue biopsy. This patient was then placed on a next-generation tyrosine kinase inhibitor and has subsequently demonstrated radiographic response to this change in treatment." "These study data further build on clinical evidence that the Target Selector™ affords non-invasive profiling of a tumor's genomic landscape by monitoring treatment response and early detection of the emergence of resistance," said Veena Singh, MD, Biocept's Senior Vice President and Senior Medical Director. "The high concordance and level of specificity and sensitivity of the Target Selector™ assay shown in this study suggest that it has utility in the re-stratification of patients due to tumoral heterogeneity in order to qualify them for TKI therapy. "Further, the Target Selector™ is performed on a simple blood sample which is also known as a liquid biopsy. Liquid biopsies are used when the initial diagnostic tissue biopsy sample is depleted, which can occur as much as 20% of the time. These patients are often too sick for additional invasive tissue sampling or refuse another surgical procedure. In addition, our liquid biopsy tests provide cost savings when compared with surgical tissue biopsies, thus delivering an added economic benefit to the healthcare system in general," added Dr. Singh.